Posts by: Alice Melão

News

Worldwide Clinical Trials was selected as the Clinical Research Organization (CRO) to run a Phase 3 study of the investigational stem-cell therapy NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm Cell ... Read more

June 30, 2017June 30, 2017

Radicava and Its Swift FDA Approval Are Reasons for Hope, ALS Association Official Says

News

Radicava (edaravone), the first approved treatment for amyotrophic lateral sclerosis in 22 years, is being welcomed with “a great deal of excitement” in the ALS community, an ALS Association executive ... Read more

June 30, 2017June 30, 2017

Transcript of Interview with ALS Association’s Calaneet Balas on Radicava, the FDA, Insurance and Pricing

News

Below is a transcript of the ALS News Today interview with Calaneet Balas, executive vice president of strategy for the ALS Association. The nonprofit association, established in 1985, is active in promoting ... Read more

June 29, 2017June 29, 2017

Edaravone, Now Known as Radicava, Has Been ‘Minor Miracle’ for Some, ALS Worldwide Co-director Says

News

Edaravone — now more widely known by its U.S. brand name, Radicava — has produced “a minor miracle” for some amyotrophic lateral sclerosis patients, said Stephen Byer, co-director of ... Read more

June 16, 2017

Stem Cell Transplantation Shows Potential as ALS Therapy, Study Suggests

News

Stem cell transplantation in patients with amyotrophic lateral sclerosis (ALS) has the potential to be “an important alternative strategy” in treating the disease, a new study suggests. In recent decades, ... Read more

June 5, 2017June 5, 2017

Discovery of Molecular Trigger of Motor Neuron Death Could Aid ALS Treatment Research

News

Researchers have identified the sequence of molecular events leading to motor neuron death in amyotrophic lateral sclerosis (ALS), an important step forward that may lead to new therapies to halt this ... Read more

June 2, 2017June 2, 2017

Radicava’s Journey to Becoming 1st ALS Treatment in 22 Years, an Interview with MT Pharma America

News

Radicava, also known by its generic name edaravone, is the first treatment approved by U.S. Food and Drug Administration (FDA) in more than two decades to help amyotrophic lateral sclerosis (ALS) ... Read more

May 24, 2017May 25, 2017

Potential ALS Therapy Based on Cancer Treatment Rituximab Shows Promise

News

Researchers at Ben-Gurion University (BGU) believe that an existing FDA-approved anti-cancer drug, rituximab, could be modified and used to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s ... Read more

May 9, 2017

New Antibody Armanezumab May Be Possible Therapeutic Strategy for ALS

News

Researchers have developed an antibody, called armanezumab, which specifically targets defective tau protein. The molecule has potential for the treatment of amyotrophic lateral sclerosis (ALS), among other diseases. According ... Read more

October 4, 2016October 4, 2016

Early Signs of Bulbar Disease in ALS May Be Evident in Tongue’s Movement While Talking

News

Researchers report that evaluating a person’s control of tongue movement during speech can help to diagnose bulbar disease, especially in its early stages, in patients with amyotrophic lateral sclerosis (ALS). ALS ... Read more